The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial
Open accessAbstract
Background & aims This study's aim was to assess the histological and metabolic effects of n-3 polyunsaturated fatty acids (PUFAs) vs. placebo while adjusting for the impact of age and weight change in NASH patients. (ClinicalTrials.gov: NCT00681408).Methods Forty-one subjects with non-cirrhotic NASH were enrolled, and 34 completed the study. 17 received n-3 fish oil 3000 mg/day and 17 received placebo daily for 1 year with typical counselling on caloric intake and physical activity for all subjects.Results N-3- and placebo-treated groups showed no significant difference for the primary end point of NASH activity score (NAS) reduction ⩾ 2 points without fibrosis progression after adjustment for known covariates (n-3, 4/17 (23.5%); placebo, 3/17, (17.6%), p = 0.99). Among subjects with increased or stable weight, n-3 subjects showed a larger decrease in liver fat content by MRI than placebo-treated subjects (p = 0.014 for 2nd quartile, p = 0.003 for 3rd quartile of weight change). N-3 treatment showed significant fat reduction on the paired analysis of image-assisted fat morphometry regardless of weight loss or gain. Exercise capacity remained markedly reduced in all subjects. No independent effects on markers of hepatocyte injury or insulin sensitivity indices were observed.Conclusion N-3 PUFAs at 3000 mg/day for one year did not lead to an improvement in the primary outcome of histological activity in NASH patients (⩾ 2 point NAS reduction). N-3 led to reduced liver fat by multiple measures. Other metabolic effects were not seen, although no detrimental effects were apparent. Whether longer duration, higher dose, or different composition of n-3 therapy would lead to additional benefits is uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, supplementation with eicosapentaenoic acid (in ethyl ester formulation) did not show any histological ef fi cacy vs . placebo in RCTs.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [387]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Compendium of physical activities: an update of activity codes and MET intensities
AINSWORTH, B. E., HASKELL, W. L., WHITT, M. C., IRWIN, M. L., SWARTZ, A. M., STRATH, S. J., O???BRIEN, W. L., BASSETT, D. R., SCHMITZ, K. H., EMPLAINCOURT, P. O., et al. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200009001-00009 · Cited by 8,497
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,112
Endres, S., Ghorbani, R., Kelley, V. E., Georgilis, K., Lonnemann, G., van der Meer, J. W. M., Cannon, J. G., Rogers, T. S., Klempner, M. S., Weber, P. C., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902023200501 · Cited by 1,911
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Research works printed but not linked: 1
- Kleiner, 2008, Creation of a continuous visual scale of ballooned hepatocytes in non-alcoholic fatty liver disease, Hepatology, 48, 815A
Cited by
Sorted by citations
Items 201–224 of 224
Plauth, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98368-6.00004-5 · Cited by 1
Shareef, M. A., Mohammed, T. R., Ali, A. T., & Alnori, H. M. (2023) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/1259/1/012083 · Cited by 2
Кручинина, М. В., Паруликова, М. В., Kurilovich, S. A., Gromov, A. A., Шашков, М. В., Sokolova, A. S., & Кручинин, В. Н. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-191-7-12-22 · Cited by 1
Li, L., Cong, C., Zhang, X., & Zhang, X. (2026) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s573711
OPINION Nonalcoholic fatty liver disease: new treatments
Hardy, T. L., Anstee, Q. M., & Day, C. P. (2015)
Omega‐3 Fatty Acid‐rich Parenteral Nutrition
Ibrahim, S. H. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001091
Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_16
Delarue, J., & Lallès, J. P. (2016) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2016.09.002
Dietary Manipulation of Gut Microbiota for Improvement of Metabolic Health
Bomhof, M. R. (2016) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/25704
Management of Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
Harrison, S. A., Pence, M. M., Stratton, A., & Torres, D. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00027-6
Bischoff, S. C., Bernal, W. E., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., Plauth, M., Скрипник, І. М., & Shvets, O. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-1-59
Ruolo dei farmaci non antidiabete nel trattamento della NAFLD
Maurizio Russello, M. L. A. (2021) · il Diabete · doi:10.30682/ildia2102c
Nieuwenhuizen, A. G., & van Schothorst, E. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-1851-0
Lipids and nonalcoholic fatty liver disease
Guo, X., & Ma, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823914-8.00009-4
Жирные кислоты мембран эритроцитов как биомаркеры неалкогольной жировой болезни печени у мужчин
Кручинина, М. В., Паруликова, М. В., Pershina, N. E., & Кручинина, Э. В. (2023) · Ateroscleroz · doi:10.52727/2078-256x-2022-18-4-362-380
Андреевна, С. Н., Владимировна, Г. И., & Мазурчик, Н. В. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-3-40-45
Wang, Y.-F. (2024) · Traditional Chinese Medicine · doi:10.12677/tcm.2024.136177
Nanizawa, E., Katoh, Y., Tamaki, Y., Otsuka, S., Hatayama, N., Ishikawa, T., Hirai, S., & Naito, M. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110049
Wang, R. Z., Zhang, W. S., Qiang, J. C., Zhu, F., Jin, Y. L., & Xu, L. (2023) · Figshare · doi:10.6084/m9.figshare.24761414
Kouti, T., Christodoulou, P., Christodoulides, S., Protopapa, F., Michaeloudes, C., & Farazi, P. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1767917
Alqahtani, A., Wang, M., Liu, L., LiYuan, R. A. N., Liu, C., Liang, Y., Yu, J., Wu, Y., & Guan, Q. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71882
Yang, X., Ning, J., Wang, L., Wang, X., Yang, H., Ma, Z., Ji, C., Chang, Q., Zhao, Y., & Xia, Y. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100026
Loss of dmrt2a Alters Hepatic LC-PUFA Composition and Lipid Homeostasis in Zebrafish
Hou, M., Li, D., ZHANG, Y., & Hengde, L. I. (2026) · Cells · doi:10.3390/cells15191763
Syed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643
Metadata
- Authors
- Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., Binder, L. P., Simmons-Egolf, W. D., Burks, S. G., Bao, Y., Taylor, A. G., Rodriguez, J., & Caldwell, S. H.
- Affiliations
- University of Virginia Health System (US)
- University of Virginia (US)
- Medical University of Graz (AT)
- University of Calgary (CA)
- Corresponding author
- Argo, Curtis K.
- Caldwell, Stephen H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 62
- Issue
- 1
- Pages
- 190-197
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC4272639
- OpenAlex
- W2019810874
- Cited by
- 224
- References
- 37
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 17 · 2023: 21 · 2022: 13 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 30 · 2017: 24 · 2016: 19 · 2015: 21
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Virginia
- National Center for Research Resources (5 M01 RR00847, M01RR000847)
- National Center for Complementary and Integrative Health (R21AT002901, 5R21AT2901-2)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- omega-3 polyunsaturated fatty acids, nonalcoholic steatohepatitis, liver fat, weight change, exercise capacity, insulin sensitivity, hepatocyte injury, non-cirrhotic liver disease
- MeSH terms
- Adult, Aged, Biopsy, Double-Blind Method, Energy Metabolism, Female, Follow-Up Studies, Humans, Liver, Male, Middle Aged, Retrospective Studies, Fatty Acids, Omega-3, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
